Line 92: |
Line 92: |
| t(14;14) ~25% | | t(14;14) ~25% |
| |Yes | | |Yes |
− | |Yes | + | |No |
− | |Yes (although not established as a therapeutic marker, it associated with poor response to conventional chemotherapy) | + | |No |
| |These genetic abnormalities serve as diagnostic markers and generally indicate an aggressive disease. This is due to their role in overexpressing oncogenes like ''TCL1A''. '''Major diagnostic criteria'''.<ref name=":6" /> | | |These genetic abnormalities serve as diagnostic markers and generally indicate an aggressive disease. This is due to their role in overexpressing oncogenes like ''TCL1A''. '''Major diagnostic criteria'''.<ref name=":6" /> |
| |- | | |- |
Line 102: |
Line 102: |
| |Yes | | |Yes |
| |No | | |No |
− | |Yes (although not established as a therapeutic marker, it associated with poor response to conventional chemotherapy) | + | |No |
| |'''Major diagnostic criteria'''.<ref name=":6" /> | | |'''Major diagnostic criteria'''.<ref name=":6" /> |
| |} | | |} |
Line 158: |
Line 158: |
| |Yes | | |Yes |
| |Yes | | |Yes |
− | |Yes | + | |Yes (poor |
| |Frequent, '''Minor diagnostic criteria'''.<ref name=":6" /> | | |Frequent, '''Minor diagnostic criteria'''.<ref name=":6" /> |
| |- | | |- |
Line 168: |
Line 168: |
| |Yes | | |Yes |
| |No | | |No |
− | |Haploinsufficiency of the CDKN1B gene at the 12p13 locus contributes to the development of T-PLL.<ref>{{Cite journal|last=Le Toriellec|first=Emilie|last2=Despouy|first2=Gilles|last3=Pierron|first3=Gaëlle|last4=Gaye|first4=Nogaye|last5=Joiner|first5=Marjorie|last6=Bellanger|first6=Dorine|last7=Vincent-Salomon|first7=Anne|last8=Stern|first8=Marc-Henri|date=2008-02-15|title=Haploinsufficiency of CDKN1B contributes to leukemogenesis in T-cell prolymphocytic leukemia|url=https://pubmed.ncbi.nlm.nih.gov/18073348|journal=Blood|volume=111|issue=4|pages=2321–2328|doi=10.1182/blood-2007-06-095570|issn=0006-4971|pmid=18073348}}</ref> | + | |Haploinsufficiency of the ''CDKN1B'' gene at the 12p13 locus contributes to the development of T-PLL.<ref>{{Cite journal|last=Le Toriellec|first=Emilie|last2=Despouy|first2=Gilles|last3=Pierron|first3=Gaëlle|last4=Gaye|first4=Nogaye|last5=Joiner|first5=Marjorie|last6=Bellanger|first6=Dorine|last7=Vincent-Salomon|first7=Anne|last8=Stern|first8=Marc-Henri|date=2008-02-15|title=Haploinsufficiency of CDKN1B contributes to leukemogenesis in T-cell prolymphocytic leukemia|url=https://pubmed.ncbi.nlm.nih.gov/18073348|journal=Blood|volume=111|issue=4|pages=2321–2328|doi=10.1182/blood-2007-06-095570|issn=0006-4971|pmid=18073348}}</ref> |
| '''Minor diagnostic criteria'''.<ref name=":6" /> | | '''Minor diagnostic criteria'''.<ref name=":6" /> |
| |- | | |- |
Line 187: |
Line 187: |
| |Yes | | |Yes |
| |Yes (resistance to therapy) | | |Yes (resistance to therapy) |
− | |May include TP53 gene at 17p13.1. <ref name=":7" /> | + | |May include ''TP53'' gene at 17p13.1 <ref name=":7" /> |
| |- | | |- |
| |22 | | |22 |
Line 200: |
Line 200: |
| |No | | |No |
| |No | | |No |
− | |Leading to the dysregulation of genes such as BCL11B, which is crucial in T-cell development and function.<ref name=":0" /> | + | |Leading to the dysregulation of genes such as ''BCL11B'', which is crucial in T-cell development and function.<ref name=":0" /> |
| '''Minor diagnostic criteria'''.<ref name=":6" /> | | '''Minor diagnostic criteria'''.<ref name=":6" /> |
| |} | | |} |
Line 232: |
Line 232: |
| t(14;14)(q11.2;q32.1) | | t(14;14)(q11.2;q32.1) |
| |Yes | | |Yes |
− | |Yes | + | |No |
− | |Yes | + | |No |
| |The most common chromosomal abnormality in T-PLL involves an inversion of chromosome 14, with breakpoints at q11.2 and q32.1, observed in about 60-80% of patients and described as inv(14). Additionally, in 10-20% of cases, there is a translocation t(14;14)(q11.2;q32.1) | | |The most common chromosomal abnormality in T-PLL involves an inversion of chromosome 14, with breakpoints at q11.2 and q32.1, observed in about 60-80% of patients and described as inv(14). Additionally, in 10-20% of cases, there is a translocation t(14;14)(q11.2;q32.1) |
| |} | | |} |
| ==Gene Mutations (SNV / INDEL)== | | ==Gene Mutations (SNV / INDEL)== |
− | Although gene mutations beyond TCL1 family alterations are not yet recognized as diagnostic criteria and remain under investigation for T-PLL, the mutational landscape of T-PLL provides valuable insights. These discoveries open up potential avenues for novel targeted therapies in treating this aggressive form of leukemia. | + | Although gene mutations beyond ''TCL1'' family alterations are not yet recognized as diagnostic criteria and remain under investigation for T-PLL, the mutational landscape of T-PLL provides valuable insights. These discoveries open up potential avenues for novel targeted therapies in treating this aggressive form of leukemia. |
| | | |
| Deletions and mutations of the ATM gene (present in up to 90% of T-PLL cases but typically absent in other mature T-cell malignancies) are considered highly indicative for a diagnosis of suspected TCL1 family-negative T-PLL.<ref name=":8">{{Cite journal|last=Schrader|first=A.|last2=Crispatzu|first2=G.|last3=Oberbeck|first3=S.|last4=Mayer|first4=P.|last5=Pützer|first5=S.|last6=von Jan|first6=J.|last7=Vasyutina|first7=E.|last8=Warner|first8=K.|last9=Weit|first9=N.|date=2018-02-15|title=Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL|url=https://pubmed.ncbi.nlm.nih.gov/29449575|journal=Nature Communications|volume=9|issue=1|pages=697|doi=10.1038/s41467-017-02688-6|issn=2041-1723|pmc=5814445|pmid=29449575}}</ref><ref name=":3" /> | | Deletions and mutations of the ATM gene (present in up to 90% of T-PLL cases but typically absent in other mature T-cell malignancies) are considered highly indicative for a diagnosis of suspected TCL1 family-negative T-PLL.<ref name=":8">{{Cite journal|last=Schrader|first=A.|last2=Crispatzu|first2=G.|last3=Oberbeck|first3=S.|last4=Mayer|first4=P.|last5=Pützer|first5=S.|last6=von Jan|first6=J.|last7=Vasyutina|first7=E.|last8=Warner|first8=K.|last9=Weit|first9=N.|date=2018-02-15|title=Actionable perturbations of damage responses by TCL1/ATM and epigenetic lesions form the basis of T-PLL|url=https://pubmed.ncbi.nlm.nih.gov/29449575|journal=Nature Communications|volume=9|issue=1|pages=697|doi=10.1038/s41467-017-02688-6|issn=2041-1723|pmc=5814445|pmid=29449575}}</ref><ref name=":3" /> |
Line 289: |
Line 289: |
| |- | | |- |
| |''EZH2'' | | |''EZH2'' |
− | |Oncogene, TSG | + | |Both oncogene and TSG |
| |16% (COSMIC) | | |16% (COSMIC) |
| |''JAK/STAT'' pathway<ref name=":1" /><ref name=":2" /> | | |''JAK/STAT'' pathway<ref name=":1" /><ref name=":2" /> |
| |None specified | | |None specified |
| |No | | |No |
− | |Yes | + | |No (see note) |
| |See note | | |See note |
| |''EZH2'' inhibitors like tazemetostat have shown efficacy in other hematologic malignancies, providing a rationale for their potential use in T-PLL | | |''EZH2'' inhibitors like tazemetostat have shown efficacy in other hematologic malignancies, providing a rationale for their potential use in T-PLL |
Line 371: |
Line 371: |
| |} | | |} |
| ==Genetic Diagnostic Testing Methods== | | ==Genetic Diagnostic Testing Methods== |
− | The genetic diagnostic process involves detecting clonal rearrangements of the TR gene and rearrangements of the ''TCL1'' gene at the ''TRB'' or ''TRG'' loci.
| + | Diagnosing T-PLL involves a combination of clinical evaluation, laboratory tests, imaging studies, and genetic testing to identify diagnostic criteria. T-cell clonality can be confirmed through PCR, NGS, or flow cytometry.<ref>{{Cite journal|last=Kotrova|first=Michaela|last2=Novakova|first2=Michaela|last3=Oberbeck|first3=Sebastian|last4=Mayer|first4=Petra|last5=Schrader|first5=Alexandra|last6=Knecht|first6=Henrik|last7=Hrusak|first7=Ondrej|last8=Herling|first8=Marco|last9=Brüggemann|first9=Monika|date=2018-11|title=Next-generation amplicon TRB locus sequencing can overcome limitations of flow-cytometric Vβ expression analysis and confirms clonality in all T-cell prolymphocytic leukemia cases|url=https://pubmed.ncbi.nlm.nih.gov/30414304|journal=Cytometry. Part A: The Journal of the International Society for Analytical Cytology|volume=93|issue=11|pages=1118–1124|doi=10.1002/cyto.a.23604|issn=1552-4930|pmid=30414304}}</ref> Patients with T-PLL often exhibit complex karyotypes with recurrent genetic features that aid in diagnosis. Therefore, cytogenetic studies are useful for distinguishing T-PLL from other T-lymphoproliferative disorders.<ref name=":6" /> |
| + | |
| + | * '''Cytogenetic Analysis''' |
| + | |
| + | # Karyotyping: To identify characteristic chromosomal abnormalities, such as inv(14)(q11q32), t(14;14)(q11;q32), or other translocations involving chromosome 14. '''Major diagnostic criteria''' |
| + | # Fluorescence In Situ Hybridization (FISH): To detect specific genetic abnormalities, such as TCL1 gene rearrangements as a '''Major diagnostic criterion''' or MYC as a '''Minor diagnostic criterion''' (alternatively, molecular studies could be used). see note. |
| + | |
| + | <small><u>'''Note:''' ''TCL1A'' break-apart probes specific to the 14q32 region can identify translocations involving TCL1A. When a ''TCL1A'' rearrangement is not identified and the patient has T-cell prolymphocytic leukemia/lymphoma (T-PLL), reflex testing using the ''TRAD'' break-apart probe set may be performed.</u></small> |
| + | |
| + | * '''Molecular Genetic Testing''' |
| | | |
− | *Cytogenetics (FISH, CpG-stimulated Karyotype, SNP microarray)
| + | # Polymerase Chain Reaction (PCR) and Reverse Transcription PCR (RT-PCR): To show the rearrangements of the TR gene (TCRB, TCRG loci) as a '''Major diagnostic criterion,''' and alternative to FISH rearrangements of the ''TCL1'' or ''MTCP'' genes at the ''TRD'' locus can be detected by PCR. '''Major diagnostic criteria''' |
− | *PCR for TRB/TRG
| + | # Next generation sequencing (NGS)-See note |
− | *Next-Generation Sequencing (NGS)
| |
| | | |
| + | <u>'''<small>Note:</small>''' <small>Although alterations of ''TCL1A'', ''TCL1B (TML1)'', or ''MTCP'' are present in more than 90% of cases, they are not found in 100% of cases. Taken together, assessment of clonal TCR rearrangement, cytogenetics, and FISH are relevant genetic tests to establish the diagnosis of T-PLL. Genetic sequencing is currently not a diagnostic requirement; however, it may provide information regarding the underlying pathogenesis of T-PLL or might help to identify relevant prognostic subgroups.</small></u><ref name=":6" /> |
| ==Familial Forms== | | ==Familial Forms== |
− | While there is no noticeable familial clustering of T-cell prolymphocytic leukemia (T-PLL), a subset of cases can develop in the context of ataxia-telangiectasia (AT). AT is characterized by germline mutations in the ATM gene, and patients with AT are at an increased risk for various malignancies, including T-PLL. In these cases, biallelic inactivation of the ATM tumor suppressor gene occurs, with about 10% to 15% penetrance of the tumor phenotype by early adulthood. T-PLL represents nearly 3% of all malignancies in patients with ataxia-telangiectasia. <ref>{{Cite journal|last=Suarez|first=Felipe|last2=Mahlaoui|first2=Nizar|last3=Canioni|first3=Danielle|last4=Andriamanga|first4=Chantal|last5=Dubois d'Enghien|first5=Catherine|last6=Brousse|first6=Nicole|last7=Jais|first7=Jean-Philippe|last8=Fischer|first8=Alain|last9=Hermine|first9=Olivier|date=2015-01-10|title=Incidence, presentation, and prognosis of malignancies in ataxia-telangiectasia: a report from the French national registry of primary immune deficiencies|url=https://pubmed.ncbi.nlm.nih.gov/25488969|journal=Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology|volume=33|issue=2|pages=202–208|doi=10.1200/JCO.2014.56.5101|issn=1527-7755|pmid=25488969}}</ref> <ref>{{Cite journal|last=Taylor|first=A. M.|last2=Metcalfe|first2=J. A.|last3=Thick|first3=J.|last4=Mak|first4=Y. F.|date=1996-01-15|title=Leukemia and lymphoma in ataxia telangiectasia|url=https://pubmed.ncbi.nlm.nih.gov/8555463|journal=Blood|volume=87|issue=2|pages=423–438|issn=0006-4971|pmid=8555463}}</ref> <ref>{{Cite journal|last=Li|first=Geling|last2=Waite|first2=Emily|last3=Wolfson|first3=Julie|date=2017-12-26|title=T-cell prolymphocytic leukemia in an adolescent with ataxia-telangiectasia: novel approach with a JAK3 inhibitor (tofacitinib)|url=https://pubmed.ncbi.nlm.nih.gov/29296924|journal=Blood Advances|volume=1|issue=27|pages=2724–2728|doi=10.1182/bloodadvances.2017010470|issn=2473-9529|pmc=5745136|pmid=29296924}}</ref> | + | While there is no noticeable familial clustering of T-cell prolymphocytic leukemia (T-PLL), a subset of cases can develop in the context of ataxia-telangiectasia (AT). AT is characterized by germline mutations in the ''ATM'' gene, and patients with AT are at an increased risk for various malignancies, including T-PLL. In these cases, biallelic inactivation of the ''ATM'' tumor suppressor gene occurs, with about 10% to 15% penetrance of the tumor phenotype by early adulthood. T-PLL represents nearly 3% of all malignancies in patients with ataxia-telangiectasia. <ref>{{Cite journal|last=Suarez|first=Felipe|last2=Mahlaoui|first2=Nizar|last3=Canioni|first3=Danielle|last4=Andriamanga|first4=Chantal|last5=Dubois d'Enghien|first5=Catherine|last6=Brousse|first6=Nicole|last7=Jais|first7=Jean-Philippe|last8=Fischer|first8=Alain|last9=Hermine|first9=Olivier|date=2015-01-10|title=Incidence, presentation, and prognosis of malignancies in ataxia-telangiectasia: a report from the French national registry of primary immune deficiencies|url=https://pubmed.ncbi.nlm.nih.gov/25488969|journal=Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology|volume=33|issue=2|pages=202–208|doi=10.1200/JCO.2014.56.5101|issn=1527-7755|pmid=25488969}}</ref> <ref>{{Cite journal|last=Taylor|first=A. M.|last2=Metcalfe|first2=J. A.|last3=Thick|first3=J.|last4=Mak|first4=Y. F.|date=1996-01-15|title=Leukemia and lymphoma in ataxia telangiectasia|url=https://pubmed.ncbi.nlm.nih.gov/8555463|journal=Blood|volume=87|issue=2|pages=423–438|issn=0006-4971|pmid=8555463}}</ref> <ref>{{Cite journal|last=Li|first=Geling|last2=Waite|first2=Emily|last3=Wolfson|first3=Julie|date=2017-12-26|title=T-cell prolymphocytic leukemia in an adolescent with ataxia-telangiectasia: novel approach with a JAK3 inhibitor (tofacitinib)|url=https://pubmed.ncbi.nlm.nih.gov/29296924|journal=Blood Advances|volume=1|issue=27|pages=2724–2728|doi=10.1182/bloodadvances.2017010470|issn=2473-9529|pmc=5745136|pmid=29296924}}</ref> |
| ==Additional Information== | | ==Additional Information== |
| In T-PLL, the rapid growth of the disease necessitates immediate initiation of treatment. The most effective first-line treatment is alemtuzumab, an anti-CD52 antibody with remission rates over 80%. However, these remissions usually last only 1-2 years. To potentially extend remission, eligible patients are advised to undergo allogeneic blood stem cell transplantation (allo-SCT) during their first complete remission, which can lead to longer remission durations of over 4-5 years for 15-30% of patients. Consequently, the prognosis for T-PLL remains poor, with median overall survival times under two years and five-year survival rates below 5%[https://clinicaltrials.gov/study/NCT03989466 . Ongoing studies are exploring molecularly targeted drugs and signaling pathway inhibitors, for routine clinical use in treating T-PLL.] | | In T-PLL, the rapid growth of the disease necessitates immediate initiation of treatment. The most effective first-line treatment is alemtuzumab, an anti-CD52 antibody with remission rates over 80%. However, these remissions usually last only 1-2 years. To potentially extend remission, eligible patients are advised to undergo allogeneic blood stem cell transplantation (allo-SCT) during their first complete remission, which can lead to longer remission durations of over 4-5 years for 15-30% of patients. Consequently, the prognosis for T-PLL remains poor, with median overall survival times under two years and five-year survival rates below 5%[https://clinicaltrials.gov/study/NCT03989466 . Ongoing studies are exploring molecularly targeted drugs and signaling pathway inhibitors, for routine clinical use in treating T-PLL.] |